FXR-IBD

Industry-Academia exchange to further FXR-based therapeutic intervention and non-invasive diagnosis in Inflammatory Bowel Disease

Coordinatore	UNIVERSITAIR MEDISCH CENTRUM UTRECHT    more  Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX contact info Titolo: Mr. Nome: Joost Cognome: Warsanis Email: send email Telefono: +31 88 7568064 Fax: +31 88 7553660
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	1˙486˙100 €
EC contributo	1˙486˙100 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-IAPP
Funding Scheme	MC-IAPP
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-01-01   -   2017-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAIR MEDISCH CENTRUM UTRECHT  Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX contact info Titolo: Mr. Nome: Joost Cognome: Warsanis Email: send email Telefono: +31 88 7568064 Fax: +31 88 7553660	NL (UTRECHT)	coordinator	806˙692.50
2	TES PHARMA SRL  Organization address address: VIA SETTEVALLI 556 city: PERUGIA postcode: 6129 contact info Titolo: Dr. Nome: Graeme Cognome: Robertson Email: send email Telefono: +39 335 731 1445	IT (PERUGIA)	participant	383˙018.30
3	ENTEROME SA  Organization address address: AVENUE LEDRU ROLLIN 94/96 city: PARIS postcode: 75011 contact info Titolo: Ms. Nome: Marie-Laure Cognome: Bouttier Email: send email Telefono: +33 175772786	FR (PARIS)	participant	296˙389.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Inflammatory Bowel Disease (IBD) covers a cluster of disorders characterized by chronic intestinal inflammation which affects approximately 0.2% of the global human population. Current treatment options often fail, are marred by side-effects and undergoing regular endoscopy to monitor and manage the disease is often a burden to the patient. In this study we aim to: 1. Develop a novel treatment for IBD, using the recently described anti-inflammatory effects of agonists capable of selectively activating the Farnesoid X nuclear Receptor (FXR) as a pharmaceutical lead. 2. Develop a non-invasive diagnostic tool using well-described changes in the gut microbiome of people affected with IBD as a marker to diagnose and monitor disease progression or remission in stool samples. In order to achieve these objectives we will develop 2 novel biological high-throughput screening assays (luciferase- and cofactor interaction-based) with which we can assay selective activity of FXR. These screening assays will be dictated by fundamental scientific insights in FXR-mediated activity and signal transduction. Meanwhile, a new non-invasive microbiome-based diagnostic tool will be generated and validated using feces from well-defined patients with IBD. Ultimately, this project will culminate in proof of principle using first-in-men clinical trials to demonstrate that the anti-inflammatory activity of FXR agonists can be used to treat IBD successfully in vivo. As illustrated above, the development of a new IBD-treatment option and the validation of a novel diagnostic tool require the input of several domains of scientific knowledge, such as medicine, microbiome-genetics, pharmacology and molecular biology. The free flow of ideas between disciplines and unfettered access to specialist expertise will greatly speed up the development of these novel approaches to the treatment and diagnosis of IBD.'